What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.

The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: EU/1/02/227/005, EU/1/02/227/004, EU/1/02/227/002, EU/1/02/227/001.

NEULASTA

Package leaflet: Information for the user

Neulasta 6 mg solution for injection

pegfilgrastim

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
  • Whilst wearing the Neulasta on body injector it is important that you keep the Alert Card provided by your doctor, pharmacist or nurse with you. It contains important advice on how to monitor your device for medication errors including under dose leading to lack of effect, and when to seek immediate medical attention.

What is in this leaflet

1. What Neulasta is and what it is used for
2. What you need to know before you use Neulasta
3. How to use Neulasta
4. Possible side effects
5. How to store Neulasta
6. Contents of the pack and other information

1. What Neulasta is and what it is used for

Neulasta contains the active substance pegfilgrastim. Pegfilgrastim is a protein produced by biotechnology in bacteria called E. coli. It belongs to a group of proteins called cytokines, and is very similar to a natural protein (granulocyte-colony stimulating factor) produced by your own body.

Neulasta is used to reduce the duration of neutropenia (low white blood cell count) and the occurrence of febrile neutropenia (low white blood cell count with a fever) which can be caused by the use of cytotoxic chemotherapy (medicines that destroy rapidly growing cells). White blood cells are important as they help your body fight infection. These cells are very sensitive to the effects of chemotherapy which can cause the number of these cells in your body to decrease. If white blood cells fall to a low level there may not be enough left in the body to fight bacteria and you may have an increased risk of infection.

Your doctor has given you Neulasta to encourage your bone marrow (part of the bone which makes blood cells) to produce more white blood cells that help your body fight infection.

2. What you need to know before you use Neulasta

Do not use Neulasta

  • if you are allergic to pegfilgrastim, filgrastim, or any of the other ingredients of this medicine.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Neulasta:

  • if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), redness and flushing, skin rash and areas of the skin that itch.
  • if you have an allergy to latex. The needle cap on the pre-filled syringe contains a derivative of latex and may cause severe allergic reactions.
  • if you have an allergy to acrylic adhesives. The on-body injector uses acrylic adhesive and may result in an allergic reaction.
  • if you experience a cough, fever and difficulty breathing. This can be a sign of Acute Respiratory Distress Syndrome (ARDS).
  • if you have any of the following or combination of the following side effects:
    • swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness.
    These could be symptoms of a condition called “Capillary Leak Syndrome” which causes blood to leak from the small blood vessels into your body. See section 4.
  • if you get left upper abdominal pain or pain at the tip of your shoulder. This may be a sign of a problem with your spleen (splenomegaly).
  • if you have recently had a serious lung infection (pneumonia), fluid in the lungs (pulmonary oedema), inflammation of the lungs (interstitial lung disease) or an abnormal chest x-ray (lung infiltration).
  • if you are aware of any altered blood cell counts (e.g. increase in white blood cells or anaemia) or decreased blood platelet counts, which reduces the ability of your blood to clot (thrombocytopenia). Your doctor may want to monitor you more closely.
  • if you have sickle cell anaemia. Your doctor may monitor your condition more closely.
  • if you have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing these could be signs of a severe allergic reaction.
  • Inflammation of aorta (the large blood vessel which transports blood from the heart to the body) has been reported rarely in cancer patients and healthy donors. The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience those symptoms.

Your doctor will check your blood and urine regularly as Neulasta can harm the tiny filters inside your kidneys (glomerulonephritis).

You should talk to your doctor about your risks of developing cancers of the blood. If you develop or are likely to develop cancers of the blood, you should not use Neulasta, unless instructed by your doctor.

Loss of response to pegfilgrastim

If you experience a loss of response or failure to maintain a response with pegfilgrastim treatment, your doctor will investigate the reasons why including whether you have developed antibodies which neutralise pegfilgrastim’s activity.

Other medicines and Neulasta

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine. Neulasta has not been tested in pregnant women. It is important to tell your doctor if you:

  • are pregnant;
  • think you may be pregnant; or
  • are planning to have a baby.

If you become pregnant during Neulasta treatment, please inform your doctor. You may be encouraged to enrol in Amgen’s Pregnancy Surveillance programme. Local representative contact details are provided in section 6 of this leaflet.

Unless your doctor directs you otherwise, you must stop breast-feeding if you use Neulasta.

If you are nursing during Neulasta treatment, you may be encouraged to enrol in Amgen’s Lactation Surveillance programme. Local representative contact details are provided in section 6 of this leaflet.

Driving and using machines

Neulasta has no or negligible effect on the ability to drive or use machines.

Neulasta contains sorbitol (E420) and sodium acetate

Neulasta contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.

This medicine contains less than 1 mmol (23 mg) sodium per 6 mg dose, that is to say essentially ‘sodium-free’.

3. How to use Neulasta

Neulasta is for use in adults aged 18 and over.

Always take Neulasta exactly as your doctor has told you. You should check with your doctor or pharmacist if you are unsure. The usual dose is one 6 mg subcutaneous injection (injection under your skin) and it should be given at least 24 hours after your last dose of chemotherapy at the end of each chemotherapy cycle.

Injecting Neulasta yourself

Your doctor may decide that it would be more convenient for you to inject Neulasta yourself. Your doctor or nurse will show you how to inject yourself. Do not try to inject yourself if you have not been trained.

For further instructions on how to inject yourself with Neulasta, please read the section at the end of this leaflet.

Do not shake Neulasta vigorously as this may affect its activity.

Using Neulasta with the on-body injector

Your doctor may decide that it would be more convenient for you to use Neulasta with the on-body injector. For further information on use with the on-body injector, please read the instructions for use at the end of this leaflet.

Check the instructions at the end of this leaflet and contact your healthcare provider if:

  • during themonitoring of your on-body injector you are concerned that it is leaking; or
  • after the injection is complete you are concerned that you may not have received the full dose.

If you use more Neulasta than you should

If you use more Neulasta than you should contact your doctor, pharmacist or nurse.

If you forget to inject Neulasta

If you are injecting yourself and have forgotten your dose of Neulasta, you should contact your doctor to discuss when you should inject the next dose.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Please tell your doctor immediately if you have any of the following or combination of the following side effects:

  • swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness. These symptoms generally develop in a rapid fashion.

These could be symptoms of an uncommon (may affect up to 1 in 100 people) condition called “Capillary Leak Syndrome” which causes blood to leak from the small blood vessels into your body and needs urgent medical attention.

Very common side effects (may affect more than 1 in 10 people):

  • bone pain. Your doctor will tell you what you can take to ease the bone pain.
  • nausea and headaches.

Common side effects (may affect up to 1 in 10 people):

  • rash, itchy red raised bumps (contact dermatitis/local skin reactions) have been seen with the on-body injector.
  • pain at the site of injection.
  • application site reactions which may include redness, bleeding, bruising, pain and discomfort have been seen with the on-body injector.
  • general aches and pains in the joints and muscles.
  • some changes may occur in your blood, but these will be detected by routine blood tests. Your white blood cell count may become high for a short period of time. Your platelet count may become low which might result in bruising.

Uncommon side effects (may affect up to 1 in 100 people):

  • allergic-type reactions, including redness and flushing, skin rash, and raised areas of the skin that itch.
  • serious allergic reactions, including anaphylaxis (weakness, drop in blood pressure, difficulty breathing, swelling of the face).
  • increased spleen size.
  • spleen rupture. Some cases of splenic rupture were fatal. It is important that you contact your doctor immediately if you experience pain in the upper left side of the abdomen or left shoulder pain since this may relate to a problem with your spleen.
  • breathing problems. If you have a cough, fever and difficulty breathing please tell your doctor.
  • Sweet’s syndrome (plum-coloured, raised, painful lesions on the limbs and sometimes the face and neck with fever) has occurred but other factors may play a role.
  • cutaneous vasculitis (inflammation of the blood vessels in the skin).
  • damage to the tiny filters inside your kidneys (glomerulonephritis).
  • redness at the site of injection.
  • coughing up blood (haemoptysis).

Rare side effects (may affect up to 1 in 1000 people):

  • inflammation of aorta (the large blood vessel which transports blood from the heart to the body), see section 2.
  • bleeding from the lung (pulmonary haemorrhage).

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

United Kingdom

Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard

or search for MHRA Yellow Card in the Google Play or Apple App Store

Ireland

HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: medsafety@hpra.ie

Malta

ADR Reporting
Website: www.medicinesauthority.gov.mt/adrportal

5. How to store Neulasta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the syringe label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C).

You may take Neulasta out of the refrigerator and keep it at room temperature (not above 30°C) for no longer than 3 days. Once a syringe has been removed from the refrigerator and has reached room temperature (not above 30°C) it must either be used within 3 days or disposed of.

The syringe for use with the on-body injector must either be used within 36 hours after it has reached room temperature (not above 30°C) or disposed of.

Do not freeze. Neulasta may be used if it is accidentally frozen for a single period of less than 24 hours.

Keep the container in the outer carton in order to protect from light.

Do not use this medicine if you notice it is cloudy or there are particles in it.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What Neulasta contains

  • The active substance is pegfilgrastim. Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 mL of solution.
  • The other ingredients are sodium acetate, sorbitol (E420), polysorbate 20 and water for injections. See section 2.

What Neulasta looks like and contents of the pack

Neulasta is a clear, colourless solution for injection in a pre-filled syringe (6 mg/0.6 mL).

Each pack contains 1 glass pre-filled syringe with an attached stainless steel needle and needle cap.

The pre-filled syringe (with or without blister wrapping) may also be provided with either an automatic needle guard or with an on-body injector.

Marketing Authorisation Holder and Manufacturer

Amgen Europe B.V.
Minervum 7061
4817 ZK Breda
The Netherlands

Marketing Authorisation Holder

Amgen Europe B.V.
Minervum 7061
4817 ZK Breda
The Netherlands

Manufacturer

Amgen Technology (Ireland) Unlimited Company
Pottery Road
Dun Laoghaire
Co Dublin
Ireland

Manufacturer

Amgen NV
Telecomlaan 5-7
1831 Diegem
Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Amgen Limited
Tel: +44 (0)1223 420305

This leaflet was last revised in September 2018

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu

Instructions for injecting with the Neulasta pre-filled syringe

This section contains information on how to give yourself an injection of Neulasta. It is important that you do not try to give yourself the injection unless you have received training from your doctor, nurse, or pharmacist. If you have questions about how to inject, please ask your doctor, nurse, pharmacist for assistance.

How do you, or the person injecting you, use Neulasta pre-filled syringe?

You will need to give yourself the injection into the tissue just under the skin. This is known as a subcutaneous injection.

Equipment that you need

To give yourself a subcutaneous injection you will need:

  • a pre-filled syringe of Neulasta; and
  • alcohol wipes or similar.

What should I do before I give myself a subcutaneous injection of Neulasta?

1. Remove from the refrigerator.
2. Do not shake the pre-filled syringe.
3. Do not remove the cap from the syringe until you are ready to inject.
4. Check the expiry date on the pre-filled syringe label (EXP). Do not use it if the date has passed the last day of the month shown.
5. Check the appearance of Neulasta. It must be a clear and colourless liquid. If there are particles in it, you must not use it.
6. For a more comfortable injection, let the pre-filled syringe stand for 30 minutes to reach room temperature or hold the pre-filled syringe gently in your hand for a few minutes. Do not warm Neulasta in any other way (for example, do not warm it in a microwave or in hot water).
7. Wash your hands thoroughly.
8. Find a comfortable, well-lit, clean surface and put all the equipment you need within reach.

How do I prepare my Neulasta injection?

Before you inject Neulasta you must do the following:

1. Hold the syringe barrel and gently take the cap from the needle without twisting. Pull straight as shown in pictures 1 and 2. Do not touch the needle or push the plunger.

2. You may notice a small air bubble in the pre-filled syringe. You do not have to remove the air bubble before injecting. Injecting the solution with the air bubble is harmless.

3. You can now use the pre-filled syringe.

Where should I give my injection?

The most suitable places to inject yourself are:

  • the top of your thighs; and
  • the abdomen, except for the area around the navel.

If someone else is injecting you, they can also use the back of your arms.

How do I give my injection?

1. Clean your skin by using an alcohol wipe.
2. Pinch (without squeezing) the skin using your thumb and forefinger. Insert the needle into the skin.
3. Push the plunger down with a slow constant pressure. Push the plunger all the way down as far as it will go to inject all the liquid.
4. After injecting the liquid, remove the needle and let go of your skin.
5. If you notice a spot of blood at the injection site dab with a cotton ball or tissues. Do not rub the injection site. If needed, you may cover the injection site with a plaster.
6. Do not use any Neulasta that is left in the syringe.

Remember

Only use each syringe for one injection. If you have any problems, please ask your doctor or nurse for help and advice.

Disposing of used syringes

  • Do not put the cap back on used needles.
  • Keep used syringes out of the sight and reach of children.
  • The used syringe should be disposed of in accordance with local requirements. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Instructions for use:

Important

Before you use a Neulasta pre-filled syringe with automatic needle guard, read this important information:

  • It is important that you do not try to give yourself the injection unless you have received training from your doctor or healthcare provider.
  • Neulasta is given as an injection into the tissue just under the skin (subcutaneous injection).
  • Tell your doctor if you have an allergy to latex. The needle cap on the pre-filled syringe contains a derivative of latex and may cause severe allergic reactions.
  • Do not remove the grey needle cap from the pre-filled syringe until you are ready to inject.
  • Do not use the pre-filled syringe if it has been dropped on a hard surface. Use a new pre-filled syringe and call your doctor or healthcare provider.
  • Do not attempt to activate the pre-filled syringe prior to injection.
  • Do not attempt to remove the clear pre-filled syringe safety guard from the pre-filled syringe.
  • Do not attempt to remove the peelable label on the pre-filled syringe barrel before administering your injection.

Call your doctor or healthcare provider if you have any questions.

Step 1: Prepare

A Remove the pre-filled syringe tray from the package and gather the supplies needed for your injection: alcohol wipes, a cotton ball or gauze pad, a plaster and a sharps disposal container (not included).

For a more comfortable injection, leave the pre-filled syringe at room temperature for about 30 minutes before injecting. Wash your hands thoroughly with soap and water.

On a clean, well-lit work surface, place the new pre-filled syringe and the other supplies.

  • Do not try to warm the syringe by using a heat source such as hot water or microwave.
  • Do not leave the pre-filled syringe exposed to direct sunlight.
  • Do not shake the pre-filled syringe.
  • Keep pre-filled syringes out of the sight and reach of children.

B Open the tray, peeling away the cover. Grab the pre-filled syringe safety guard to remove the pre-filled syringe from the tray.

For safety reasons:

  • Do not grasp the plunger.
  • Do not grasp the grey needle cap.

C Inspect the medicine and pre-filled syringe.

  • Do not use the pre-filled syringe if:
    • The medicine is cloudy or there are particles in it. It must be a clear and colourless liquid.
    • Any part appears cracked or broken.
    • The grey needle cap is missing or not securely attached.
    • The expiry date printed on the label has passed the last day of the month shown.

In all cases, call your doctor or healthcare provider.

Step 2: Get ready

A Wash your hands thoroughly. Prepare and clean your injection site.

You can use:

  • Upper part of your thigh.
  • Belly, except for a 5 cm (2-inch) area right around your belly button.
  • Outer area of upper arm (only if someone else is giving you the injection).

Clean the injection site with an alcohol wipe. Let your skin dry.

  • Do not touch the injection site before injecting.

Do not inject into areas where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks.

B Carefully pull the grey needle cap straight out and away from your body.

C Pinch your injection site to create a firm surface.

It is important to keep the skin pinched when injecting.

Step 3: Inject

A Hold the pinch. INSERT the needle into skin.

  • Do not touch the cleaned area of the skin.

B PUSH the plunger with slow and constant pressure until you feel or hear a “snap”. Push all the way down through the snap.

It is important to push down through the “snap” to deliver your full dose.

C RELEASE your thumb. Then LIFT the syringe off skin.

After releasing the plunger, the pre-filled syringe safety guard will safely cover the injection needle.

  • Do not put the grey needle cap back on used pre-filled syringes.

Step 4: Finish

A Discard the used pre-filled syringe and other supplies in a sharps disposal container.

Medicines should be disposed of in accordance with local requirements. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Keep the syringe and sharps disposal container out of sight and reach of children.

  • Do not reuse the pre-filled syringe.
  • Do not recycle pre-filled syringes or throw them into household waste.

B Examine the injection site.

If there is blood, press a cotton ball or gauze pad on your injection site. Do not rub the injection site. Apply a plaster if needed.

On-body injector for Neulasta 6 mg solution for injection

Patient instructions for use

Important information

The on-body injector delivers your Neulasta dose with an under-the-skin (subcutaneous) injection. Your healthcare provider will fill the on-body injector with Neulasta and then apply it directly to your skin using an adhesive pad. The adhesive pad is water-resistant but you are advised to avoid submerging the on-body injector in water.

The on-body injector is worn for 27 hours after placement and is programmed to make sure you do not receive Neulasta any sooner than 24 hours after your chemotherapy. The on-body injector will use sounds and lights to let you know its status.

Allergies

  • Serious allergic reactions can happen with Neulasta. Ask your caregiver to be nearby for the first use. Plan to be in a place where you or your caregiver can appropriately monitor the on-body injector for Neulasta during the approximately 45 minute Neulasta delivery and for an hour after the delivery.
  • Tell your healthcare provider if you have had severe skin reactions to acrylic adhesives. If you have an allergic reaction during the delivery of Neulasta, remove the on-body injector by grabbing the edge of the adhesive pad and peeling off the on-body injector. Get emergency medical help right away.
  • Tell your healthcare provider if you have an allergy to latex. A pre-filled syringe is used to fill the on-body injector. The grey needle cap of the pre-filled syringe contains dry natural rubber, which is derived from latex. Latex may be transferred to your skin.

Activity

  • Avoid knocking or pulling the on-body injector. Consider wearing loose clothing and take care when changing clothes. There is a small cannula which sits just under your skin. If the on-body injector has been knocked or pulled, the cannula may become dislodged. If this happens, you may not receive your dose of Neulasta.
  • Avoid activities and places that may interfere with monitoring during the dosing of Neulasta. For example AVOID, travelling, driving, or operating heavy machines during 26-29 hours following application of the on-body injector (this includes the 45-minute dose delivery period plus an hour post-delivery).
  • Do not use baths, hot tubs, whirlpool baths, or saunas while wearing the on-body injector. This may affect your medicine.
  • Only expose the on-body injector to temperatures between 5°C - 40°C.
  • Do not expose the on-body injector to direct sunlight. If it is exposed to direct sunlight for more than 1 hour, it may affect your medicine. Wear the on-body injector under your clothing.
  • Do not expose the on-body injector to the following because the on-body injector may be damaged and you could be injured:
    • Diagnostic imaging (e.g. CT scan, MRI, ultrasound, x-ray).
    • Radiation treatment.
    • Oxygen rich environments, such as hyperbaric chambers (a transparent chamber with an increase in atmospheric pressure).

On-body injector becomes loose or falls off

  • Contact your healthcare provider immediately if the on-body injector comes away from your skin at any time before your full dose has been delivered, do not reapply it. There is a small cannula which sits just under your skin. If the on-body injector has been knocked or pulled, the cannula may become dislodged. If this happens, you may not receive your dose of Neulasta.

Electrical equipment

  • Keep the on-body injector at least 10 cm (4 inches) away from electrical equipment such as mobile phones, cordless telephones, microwaves and other common appliances. Failure to keep the on-body injector at least this recommended distance may interfere with its operation and can lead to a missed or incomplete dose of Neulasta.

If you have any concerns or further questions on the use of this medicine, contact your healthcare provider.

Guide to parts for on-body injector for Neulasta

The on-body injector is working properly.

Important: If at any time you hear beeping, check the status light. If it is flashing red, contact your healthcare provider immediately as you may need a replacement dose.

On-body injector placement

Important: Contact your healthcare provider immediately if you have severe pain or skin discomfort around your on-body injector.

  • Apply to intact, non-irritated skin on the stomach area abdomen or back of the arm. Use the arm only if a caregiver can help monitor the on-body injector’s status.

Step 1: Monitor your on-body injector

A For the next 27 hours, occasionally check the status light for at least 10 seconds. If the status light is flashing green, it is ok.

If the on-body injector was placed on the back of your arm, a caregiver must be available to monitor its status. Do not try to do this yourself, as you may accidently move it and dislodge the cannula from your skin leading to a missed or incomplete dose of Neulasta.

  • Be careful not to bump or knock the on-body injector off your body.
  • The on-body injector has a self-adhesive backing to attach it to the skin, do not use additional materials to hold it in place as this could dislodge the cannula leading to a missed or incomplete dose of Neulasta.
  • If the on-body injector at any time comes away from your skin before your full dose delivery, do not reapply it. Call your healthcare provider immediately as you may need a replacement dose.
  • Keep the on-body injector dry for the last 3 hours prior to the start of dose delivery. Avoid getting lotions, creams, oils or cleaning agents near the on-body injector, as these products may loosen the adhesive.
  • Do not sleep on the on-body injector or apply pressure during wear, especially during dose delivery. This may affect the on-body injector’s performance.

Important: If at any time you hear beeping, check the status light.

If it is flashing red, contact your healthcare provider immediately as you may need a replacement dose.

B After about 27 hours, your on-body injector will produce a series of beeps to let you know your dose delivery is about to begin. Do not remove the on-body injector at this time.

  • Dose delivery will start and take about 45 minutes to complete. The on-body injector will flash a fast green light.
  • Do not remove the on-body injector before the dose delivery is complete. This may result in a missed or incomplete dose of Neulasta.

Important: If at any time you hear beeping, check the status light. If it is flashing red, contact your healthcare provider immediately as you may need a replacement dose.

Step 2: Monitor Dose Delivery

For the next 45 minutes, monitor your on-body injector frequently for leaks during dose delivery.

If it was placed on the back of your arm, a caregiver must be available to monitor your on-body injector.

If the adhesive becomes noticeably wet (saturated) with fluid, or you see dripping, contact your healthcare provider immediately as you may need a replacement dose.

A Your dose delivery will take around 45 minutes to complete.

  • During this time, the on-body injector will flash a fast green light.
  • You may hear a series of clicks. This is ok.
  • When dose delivery is complete, a long beep will sound and the status light will be solid green.

Important: If at any time you hear beeping, check the status light.

If it is flashing red, contact your healthcare provider immediately.

Step 3: Remove your on-body injector when dose delivery is complete

A After the beep, check the colour of the status light.

Check to see if the status light is SOLID GREEN or has switched off. This means the dose is complete. If the dose is complete, go to the next step.

If you see the status light is flashing red, your on-body injector is not functioning properly. Remember, any time you see a status light flashing red, call your healthcare provider immediately, as you may need a replacement dose.

B Grab the edge of the adhesive pad. Slowly peel off the on-body injector.

  • If medicine has leaked or the adhesive is noticeably wet (saturated), contact your healthcare provider immediately as you may not have received your full dose and you may need a replacement dose.
  • Remove any extra adhesive using soap and water.

Important: Do not grasp the on-body injector itself to try to pull it off of your body.

Step 4: Finish

Check to see if your on-body injector is empty.

  • You should see a black line next to the 0% (empty) indicator to confirm you have received a full dose. If the on-body injector is not empty, contact your healthcare provider immediately as you may need a replacement dose.
  • Check your status light again. Watch for at least 10 seconds. If the status light is solid green or it has switched off, it is ok.
  • If you hear beeping, or when you check the status light and it is flashing red, contact your healthcare provider immediately.
  • If there is blood, press a clean cotton ball or gauze pad on the application site. Apply a plaster if needed.
  • Contact your healthcare provider immediately if you experience persistent or worsening redness or tenderness at the application site, as this can be a sign of infection.
  • After your on-body injector removal, place the on-body injector in a sharps disposal container whether the needle is exposed or not. If the needle is exposed, contact your healthcare provider immediately.

A Record the end status of your on-body injector.

  • Mark the box of the description that represents your on-body injector after it has been used.
    • Status light is solid green or the status light has switched off. This means that the delivery is complete.
    • The on-body injector leaked, contact your healthcare provider immediately as you may need a replacement dose.
    • Status light is red, contact your healthcare provider immediately as you may need a replacement dose.

B Properly dispose of the on-body injector.

  • The on-body injector contains batteries, electronics, and a needle. Dispose of it in a sharps disposal container as instructed by your healthcare provider or in accordance with local requirements.
  • Keep children away from the used on-body injector.

Attention!

What to do if you hear beeping or when you look at the status light and it is flashing red.

  • If the status light is flashing red, you may not have received your full dose and you may need a replacement dose. Contact your healthcare provider immediately.

What to do if the on-body injector adhesive becomes noticeably wet (saturated) with fluid, or you see dripping.

  • If the adhesive becomes saturated with fluid, or you see dripping, your medicine may have leaked out.
  • Even with a leak, the status light may remain green and the fill indicator may be at 0% (empty).
  • Contact your healthcare provider immediately as you may not have received your full dose and may need a replacement dose.

Note: It is normal to see a few drops of fluid at the application site, but not normal to see a noticeably wet (saturated) adhesive.

What do I do if the on-body injector comes off before the full dose is delivered?

Contact your healthcare provider immediately if the on-body injector comes away from your skin at any time before your full dose has been delivered. There is a small cannula which sits just under your skin. If the on-body injector has been knocked or moved, this may become dislodged. If this happens, you may not receive your dose of Neulasta. Do not reapply it.

What if there is blood at my application site after the on-body injector has been removed?

If there is blood, press a clean cotton ball or gauze pad on the application site. Apply a plaster if needed.

What if my application site is red or tender after on-body injector removal?

Contact your healthcare provider immediately if you experience persistent or worsening redness or tenderness at the application site, as this can be a sign of infection.